Meta-analysis of randomized trials reveals colchicine reduces major cardiovascular events by 32% in patients with established atherosclerotic disease, but timing proves crucial. The anti-inflammatory drug showed minimal benefit when started during acute events (HR 0.99) versus substantial protection in sub-acute or chronic phases (HR 0.33-0.77). Meta-regression identified time-to-initiation and cumulative dose as key moderators, though analysis was underpowered. Gastrointestinal discontinuation rates doubled with colchicine versus placebo. This precision medicine approach addresses a critical gap in cardiovascular care. Despite optimal cholesterol-lowering and blood-thinning therapies, many patients retain substantial cardiovascular risk driven by chronic vascular inflammation. Colchicine, an ancient anti-inflammatory drug, emerges as a promising addition to standard care when strategically timed. The substantial heterogeneity between trials suggests patient selection and timing windows matter significantly. However, this preprint awaits peer review, and the wide confidence intervals indicate results may change. If confirmed, these findings could reshape cardiovascular prevention by identifying optimal windows for anti-inflammatory intervention, potentially transforming outcomes for millions with atherosclerotic disease.